Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus.

Single-nucleotide polymorphisms upstream of the interleukin 28B (interferon λ3) gene (IL28B) strongly influence treatment efficacy in patients carrying hepatitis C virus (HCV) of genotype 1. In patients receiving 12 or 24 weeks of interferon-ribavirin therapy for infection with genotype 2 or 3 (n = 341), we found that rs12979860 strikingly determined the first phase of viral elimination (P < .001). In patients treated for 24 weeks, rs12979860 also predicted the rate of sustained virologic response (P = .02), especially among those with high baseline HCV RNA levels (P = .002) or older than 45 years (P = .01). Patients carrying CC(rs12979860) had higher baseline HCV RNA levels (P < .001) and did not, when treated for 12 weeks, achieve sustained virologic response more often than those carrying CT(rs1297986) or TT(rs1297986). The results indicate that IL28B gene testing may identify patients carrying genotype 2 or 3 who could benefit from extended treatment.

[1]  Harel Dahari,et al.  Modelling Hepatitis C virus Kinetics: The Relationship between the Infected Cell Loss rate and the Final Slope of Viral Decay , 2008, Antiviral therapy.

[2]  F. Chisari,et al.  Lambda Interferon Inhibits Hepatitis B and C Virus Replication , 2005, Journal of Virology.

[3]  K. Shianna,et al.  An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. , 2010, Gastroenterology.

[4]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[5]  NIH Consensus Statement on Management of Hepatitis C: 2002. , 2002, NIH consensus and state-of-the-science statements.

[6]  William M. Lee,et al.  Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. , 2010, Gastroenterology.

[7]  Harel Dahari,et al.  A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease. , 2009, Gastroenterology.

[8]  Thomas Berg,et al.  IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.

[9]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[10]  Sven Bergmann,et al.  Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. , 2010, Gastroenterology.

[11]  T Foitzi,et al.  Allelic discrimination using fluorogenic probes and the 5' nuclease assay , 1999 .

[12]  G. Norkrans,et al.  Randomized comparison of 12 or 24 weeks of peginterferon α‐2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection , 2008, Hepatology.

[13]  X. Lao,et al.  Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. , 2010, Gastroenterology.

[14]  A. Lewis-Antes,et al.  IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. , 2003, Nature immunology.